Comparison of delivery strategies for pharmacogenetic testing services

Pharmacogenetics and Genomics

Volumn 24, Issue 3, 2014, Pages 139-145

  Haga, Susanne B ^a   Moaddeb, Jivan ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Clinical implementation; Knowledge; Pharmacogenetic testing

Indexed keywords

ARTICLE; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; HEALTH CARE DELIVERY; HEALTH PRACTITIONER; HUMAN; PHARMACIST; PHARMACOGENETICS; POINT OF CARE TESTING; PRIORITY JOURNAL;

ELECTRONIC HEALTH RECORDS; EVIDENCE-BASED MEDICINE; GENETIC TESTING; HUMANS; PHARMACISTS; PHARMACOGENETICS;

EID: 84894073752     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000028     Document Type: Article

References (94)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364:1144-1153
2. Lesko LJ, Zineh I, Huang SM.What is clinical utility and why should we care? Clin Pharmacol Ther 2010; 88:729-733
3. Salari K, Watkins H, Ashley EA. Personalized medicine: Hope or hype? Eur Heart J 2012; 33:1564-1570
4. Woodcock J, Lesko LJ. Pharmacogenetics-Tailoring treatment for the outliers. N Engl J Med 2009; 360:811-813
5. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2013; 13:151-162
6. Predazzi IM, Mango R, Norata GD, Di Daniele N, Sergi D, Romeo F, et al. Pharmacogenetics in cardiovascular disorders: An update on the principal drugs. Am J Cardiovasc Drugs 2013; 13:79-85
7. Faruki H, Lai-Goldman M. Application of a pharmacogenetic test adoption model to six oncology biomarkers. Pers Med 2010; 7:441-450
8. Lai-Goldman M, Faruki H. Abacavir hypersensitivity: A model system for pharmacogenetic test adoption. Genet Med 2008; 10:874-878
9. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther 2012; 92:467-475
10. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92:87-95
11. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin Pharmacol Ther 2012; 92:235-242
12. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, et al. The 1200 patients project: Creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012; 92:446-449
13. Scarpini F, Cappellone R, Auteri A, Puccetti L. Role of genetic factors in statins side-effects. Cardiovasc Hematol Disord Drug Targets 2012; 12:35-43
14. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92:112-117
15. Perry CG, Shuldiner AR. Pharmacogenomics of anti-platelet therapy: How much evidence is enough for clinical implementatioñJ Hum Genet 2013; 58:339-345
16. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: Integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8:1678-1684
17. Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol 2013 doi: 10.1111/bcp.12230. [Epub ahead of print]
18. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332
19. Van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous ADR reports as a trigger for pharmacogenetic research: A prospective observational study in the Netherlands. Drug Saf 2009; 32:255-264
20. Howard R, Leathart JB, French DJ, Krishan E, Kohnke H, Wadelius M, et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clin Chim Acta 2011; 412:2063-2069
21. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Foreschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet 2012; 379:1705-1711
22. Shahabi P, Siest G, Visvikis-Siest S. Clinical interest of point-of-care pharmacogenomic testing: Clopidogrel behind warfarin. Pharmacogenomics 2012; 13:1215-1218
23. Selkirk CG, Weissman SM, Anderson A, Hulick PG. Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers 2013; 17:219-225
24. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet 2012; 82:388-394
25. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: Results of a nationwide survey. Clin Pharmacol Ther 2012; 91:450-458
26. Epstein RS, Moyer TP, Aubert RE, Kane O, Xia DJ, Verbrugge F, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55:2804-2812
27. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, et al. Feasibility of Implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 2013doi: 10.1002/ phar.1329. [Epub ahead of print]
28. Empey PE. Genetic predisposition to adverse drug reactions in the intensive care unit. Crit Care Med 2010; 38 (6 Suppl):S106-S116
29. Kopp BJ, Erstad BL, Allen ME, Theodorou AA, Priestley G. Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection. Crit Care Med 2006; 34:415-425
30. Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: An exploration and explanation of the reasons in Australia. Pers Med 2007; 4:191-199
31. Martin P, Morrison M. Realising the potential of genomic medicine. London: Royal Pharmaceutical Society of Great Britain; 2006; p. 143
32. Deloitte Economics. Improving the quality use of medicines in Australia: Realising the potential of pharmacogenomics; 2008. Available at: Http:// www.health.gov.au/internet/main/publishing.nsf/Content/htareview-069/ $FILE/069-BUPA%20Australia%20Group%20pt%202.pdf. [Accessed 25 November 2013]
33. Allison M. US pharmacies broaden access to pharmacogenetic tests. Nat Biotechnol 2010; 28:299-300
34. Topol EJ. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: Prescription for progress? Sci Transl Med 2010; 2:44cm22
35. Kennedy MJ, Phan H, Benavides S, Potts A, Sorensen S. The role of the pediatric pharmacist in personalized medicine and clinical pharmacogenomics for children: Pediatric pharmacogenomics working group. J Pediatr Pharmacol Ther 2011; 16:118-122
36. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011; 68:143-150
37. Padgett L, O'Connor S, Roederer M, McLeod H, Ferreri S. Pharmacogenomics in a community pharmacy: ACT now. J Am Pharm Assoc (2003) 2011; 51:189-193
38. Reiss SM. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J Am Pharm Assoc 2011; 51: E64-e74
39. Pellegrino AN, Martin MT, Tilton JJ, Touchette DR. Medication therapy management services: Definitions and outcomes. Drugs 2009; 69:393-406
40. O'Connor SK, Ferreri SP, Michaels NM, Chater RW, Viera AJ, Faruki H, et al. Making pharmacogenetic testing a reality in a community pharmacy. J Am Pharm Assoc 2012; 52:e259-e265
41. O'Connor SK, Ferreri SP, Michaels NM, Greco AJ, Viera AJ, Faruki H, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 2012; 13:955-962
42. ClinicalTrials.gov. Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy; 2012
43. Buurma H, Bouvy ML, De Smet PA, Floor-Screudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008; 33:17-23
44. Floor-Schreudering A, De Smet PA, Buurma H, Egberts AC, Bouvy ML. Documentation quality in community pharmacy: Completeness of electronic patient records after patients' first visits. Ann Pharmacother 2009; 43:1787-1794
45. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. Pharmacy data in epidemiological studies: An easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002; 11:379-384
46. Swen JJ, van der Straaten T, Wessels JA, Bouvy ML, Vlassak EE, Assendelft WJ, et al. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur J Clin Pharmacol 2012; 68:363-370
47. Van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Stricker BH, Kroon AA, de Leeuw PW, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 2009; 31:158-164
48. Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, et al. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther 2013; 35:385-398.e1
49. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012; 107:232-240
50. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010; 87:572-578
51. De Paepe P, Petrovic M, Outtier L, Van Maele G, Buylaert W. Drug interactions and adverse drug reactions in the older patients admitted to the emergency department. Acta Clin Belg 2013; 68:15-21
52. Cox ER, Halloran DR, Homan SM, Welliver S, Mager DE. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics 2008; 122:e1053-e1061
53. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2012; 9:CD008559
54. Zito JM, Safer DJ, DosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283:1025-1030
55. He YJ, McLeod HL. Ready when you are: Easing into preemptive pharmacogenetics. Clin Pharmacol Ther 2012; 92:412-414
56. National Center for Health Statistics (US), Health, United States, 2011. Prescription drug use in the past 30 days by sex, age, race, and Hispanic origin: United States, selected years 1988-1944 through 2005-2008. With special feature on socioeconomic status and health. Hyattsville, MD: U.S. Government Printing Office; 2012
57. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2004 summary. Adv Data 2006; 374:1-33
58. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012; 92:563-566
59. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010; 632:99-124
60. CDC. Hospital utilization (in non-Federal short-stay hospitals); 2013. Available at: Http://www.cdc.gov/nchs/fastats/hospital.htm. [Accessed 25 November 2013]
61. Kung S, Allen JD. Patients and clinicians report higher-Than-Average satisfaction with psychiatric genotyping for depressed inpatients. J Clin Psychiatry 2011; 72:262-263
62. Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006; 15:107-114
63. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: Clinical implementation of pharmacogenetics. Pharmacogenomics 2013; 14:723-726
64. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: Social and policy implications. Pharmacogenomics J 2008; 8:85-89
65. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18:344-360
66. Brothers KB, Langanke M, Erdmann P. Implications of the incidentalome for clinical pharmacogenomics. Summ Pharmacogenomics 2013; 14:1353-1362
67. Robienski J, Hoppe N. Current medicolegal and ethical issues in pathology. Pathologe 2013; 34:9-15
68. Westbrook MJ, Wright MF, Van Driest SL, McGregor TL, Denny JC, Zuvich RL, et al. Mapping the incidentalome: Estimating incidental findings generated through clinical pharmacogenomics testing. Genet Med 2013; 15:325-331
69. Green RC, Berg JS, Grody WW, Kalia S, Korf B, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565-574
70. Haga SB, Tindall G, O'Daniel JM. Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers 2012; 16:21-24
71. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: Development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012; 92:437-439
72. Evans BJ. Finding a liability-free space in which personalized medicine can bloom. Clin Pharmacol Ther 2007; 82:461-465
73. Marchant GE, Campos-Outcalt DE, Lindor RA. Physician liability: The next big thing for personalized medicine? Pers Med 2011; 8:457-467
74. Marchant GE, Milligan RJ, Wilhelmi B. Legal pressures and incentives for personalized medicine. Pers Med 2006; 3:391-397
75. Johnson JA. Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics 2013; 14:835-843
76. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010; 12: 686-693
77. Shah RR, Shah DR. Personalized medicine: Is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012; 74:698-721
78. Sorich MJ, McKinnon RA. Personalized medicine: Potential, barriers and contemporary issues. Curr Drug Metab 2012; 13:1000-1006
79. Bartlett G, Antoun J, Zgheib NK. Theranostics in primary care: Pharmacogenomics tests and beyond. Expert Rev Mol Diagn 2012; 12:841-855
80. Lunshof JE, Gurwitz D. Pharmacogenomic testing: Knowing more, doing better. Clin Pharmacol Ther 2012; 91:387-389
81. Nickola TJ, Green JS, Harralson AF, O'Brien TJ. The current and future state of pharmacogenomics medical education in the USA. Pharmacogenomics 2012; 13:1419-1425
82. Lesko LJ, Johnson JA. Academia at the crossroads: Education and training in pharmacogenomics. Pers Med 2012; 9:10
83. Cruthirds DL, Hughes PJ, Weaver S. Value of pharmacy services to the healthcare system: An interdisciplinary assessment. Int J Pharm Pract 2013; 21:38-45
84. Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists' effect as team members on patient care systematic review and meta-Analyses. Med Care 2010; 48:923-933
85. Swen JJ, Guchelaar HJ. Just how feasible is pharmacogenetic testing in the primary healthcare setting? Pharmacogenomics 2012; 13:507-509
86. Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: A proposed partnership between genetic counselors and pharmacists. Pharmacogenomics 2013; 14:957-968
87. AACP. Final Report of the 2007-2008 Bylaws and Policy Development Committee. Am J Pharm Educ 2008; 72:S16
88. Cavallari LH, Overholser BR, Anderson D, Boyce E, Buie L, Formea CM, et al. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. Pharmacotherapy 2010; 30:626
89. Pharmacists ASoH-S. ASHP formulary management policy position: Pharmacogenomics; 2012. Available at: Http://www.ashp.org/DocLibrary/ BestPractices/FormularyPositions.aspx. [Accessed 25 November 2013]
90. Education ACfP. Accreditation Standards and Guidelines: Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree; 2011. https://www.acpe-Accredit.org/standards/default.asp. [Accessed 25 November 2013]
91. Hresko A, Haga S. Insurance Coverage Policies for Personalized Medicine. J Pers Med 2012; 2:201-216
92. McClellan KA, Avard D, Simard J, Knoppers BM. Personalized medicine and access to health care: Potential for inequitable access? Eur J Hum Genet 2013; 21:143-147
93. Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schildcrout J, et al. Electronic health record design and implementation for pharmacogenomics: A local perspective. Genet Med 2013; 15:833-841
94. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCary CA, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011; 89:379-386